BLUEPRINT MEDICINES CORP's ticker is BPMC and the CUSIP is 09627Y109. A total of 223 filers reported holding BLUEPRINT MEDICINES CORP in Q2 2019. The put-call ratio across all filers is 0.36 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2019 | $7,514,000 | +46.4% | 93,861 | -1.4% | 0.01% | +25.0% |
Q4 2018 | $5,134,000 | -66.4% | 95,239 | -51.4% | 0.00% | -20.0% |
Q3 2018 | $15,294,000 | +127.6% | 195,922 | +85.1% | 0.01% | 0.0% |
Q2 2018 | $6,720,000 | -36.3% | 105,853 | -8.1% | 0.01% | -28.6% |
Q1 2018 | $10,557,000 | +21.1% | 115,122 | -0.4% | 0.01% | +16.7% |
Q4 2017 | $8,720,000 | +6.7% | 115,631 | -1.4% | 0.01% | 0.0% |
Q3 2017 | $8,172,000 | +32.3% | 117,296 | -3.8% | 0.01% | +50.0% |
Q2 2017 | $6,179,000 | +143.7% | 121,941 | +92.3% | 0.00% | +100.0% |
Q1 2017 | $2,536,000 | +56.8% | 63,428 | +10.1% | 0.00% | +100.0% |
Q4 2016 | $1,617,000 | -13.9% | 57,633 | -8.9% | 0.00% | 0.0% |
Q3 2016 | $1,878,000 | +44.8% | 63,229 | -1.3% | 0.00% | 0.0% |
Q2 2016 | $1,297,000 | +126.7% | 64,067 | +102.1% | 0.00% | – |
Q1 2016 | $572,000 | -31.5% | 31,706 | 0.0% | 0.00% | -100.0% |
Q4 2015 | $835,000 | +23.3% | 31,706 | 0.0% | 0.00% | 0.0% |
Q3 2015 | $677,000 | -50.9% | 31,706 | -39.1% | 0.00% | 0.0% |
Q2 2015 | $1,379,000 | – | 52,066 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management III, LLC | 559,381 | $41,098,000 | 15.69% |
Casdin Capital, LLC | 940,000 | $69,061,800,000 | 7.15% |
Ghost Tree Capital, LLC | 325,000 | $23,878,000 | 6.08% |
CADIAN CAPITAL MANAGEMENT, LP | 1,418,704 | $104,232,000 | 4.96% |
DAFNA Capital Management LLC | 123,218 | $9,053,000 | 3.40% |
BVF INC/IL | 437,565 | $32,148,000 | 3.38% |
Opaleye Management Inc. | 105,000 | $7,714,000 | 2.79% |
Cormorant Asset Management, LP | 493,000 | $36,221,000 | 2.20% |
Novo Holdings A/S | 170,667 | $12,539,000 | 2.15% |
Artal Group S.A. | 600,000 | $44,082,000 | 1.77% |